Heberprot-p was created by a team of researchers from the Center for Genetic Engineering and Biotechnology (CIGB)
More than 65 000 patients from all over Cuba have so far received the benefits of Heberprot-P, a drug first used on June, 2007, during a pilot study in the island’s central province of Sancti Spiritus.
The medication, created by a team of researchers from the Center for Genetic Engineering and Biotechnology (CIGB), is the only product in the world for the treatment of diabetic foot ulcers in advanced stages since it accelerates the healing of the lesions and significantly reduces the risk of amputation of the lower limbs.
Heberprot-p is registered in more than 20 nations, and has a patent awarded with the Gold Medal of the World Intellectual Property Organization (WIPO). Nearly 250 000 from around the world have been favoured with this terapeutic solution, the first with effective results ever.
Iris Lugo, communication specialist at CIGB, told Granma that next May 11-12, the Havana’s Riviera Hotel will host the XIX National Meeting of Extension for the Program of Integral Care to the Patient with Diabetic Foot Ulcer making use of Heberprot -P.
The event, promoted by the Ministry of Public Health in collaboration with the CIGB, will be attended by more than 250 specialists in Angiology and Vascular Surgery who, among other topics, will analyze the behavior of the Heberprot-p program and its main indicators.
Taken from www.granma.cu and translated by Escambray.